Home > Boards > US Listed > Biotechs > Amarin Corp. PLC ADS (AMRN)

You have to consider it was ONLY tested

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
fsulevine Member Profile
 
Followed By 7
Posts 2,207
Boards Moderated 0
Alias Born 05/15/15
160x600 placeholder
CEO Presenting on the Emerging Growth Conference on August 4.  Register Now InvestorsHub NewsWire - 8/2/2021 8:27:01 AM
Amarin to Report Second Quarter and Six Month 2021 Financial Results and Host Conference Call on August 5, 2021 GlobeNewswire Inc. - 7/15/2021 6:35:00 AM
CEO Presenting on the Emerging Growth / Investors Hub Joint Conference Tomorrow.  Register Now InvestorsHub NewsWire - 7/6/2021 7:00:00 AM
Sino United (OTC Pink: SUIC) $200 Million Commitment, Signs with Suntech, the Largest Taiwan O2O Company. InvestorsHub NewsWire - 6/30/2021 7:30:00 AM
CEO Presenting on the First Emerging Growth / Investors Hub Joint Conference Tomorrow!  Register Now InvestorsHub NewsWire - 6/22/2021 7:00:00 AM
Amarin falls after Supreme Court rejection on Vascepa Seeking Alpha - 6/21/2021 9:41:51 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/15/2021 8:41:22 AM
CEO's Presenting at Emerging Growth Conference Virtually Tomorrow InvestorsHub NewsWire - 6/8/2021 7:00:00 AM
Further Insights into Mechanism of Action of Icosapent Ethyl and Its Unique Form of Eicosapentaenoic Acid (EPA) Presented at ... GlobeNewswire Inc. - 6/2/2021 4:30:00 PM
CEO's Presenting at Emerging Growth Conference Virtually This Week InvestorsHub NewsWire - 5/25/2021 7:00:00 AM
Amarin to Present at Two Investor Conferences in June 2021 GlobeNewswire Inc. - 5/18/2021 6:05:00 AM
Amarin Highlights Multiple Scientific Findings for VASCEPA® (Icosapent Ethyl) and Its Unique Active Ingredient at the Americ... GlobeNewswire Inc. - 5/17/2021 4:05:00 PM
REDUCE-IT® Heart Failure Analyses by VASCEPA® (Icosapent Ethyl)-Driven Serum Eicosapentaenoic Acid (EPA) Levels Suggest Pot... GlobeNewswire Inc. - 5/15/2021 8:00:00 AM
Clinical Data and Other Research Results Regarding VASCEPA® (Icosapent Ethyl) and Its Unique Active Ingredient to Be Present... GlobeNewswire Inc. - 5/4/2021 7:00:00 AM
Amarin reports decline in Q1 revenue ahead of European launch of VAZKEPA Seeking Alpha - 4/29/2021 7:31:32 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 4/29/2021 6:36:55 AM
Amarin EPS beats by $0.07, misses on revenue Seeking Alpha - 4/29/2021 6:16:54 AM
Amarin Reports First Quarter 2021 Financial Results and Provides Business Update GlobeNewswire Inc. - 4/29/2021 6:10:00 AM
Amarin Announces Planned Retirement of Joseph T. Kennedy, EVP, General Counsel GlobeNewswire Inc. - 4/29/2021 6:00:00 AM
Amarin Q1 2021 Earnings Preview Seeking Alpha - 4/28/2021 1:06:54 PM
UK approves Amarin's Vazkepa for cardiovascular risk reduction Seeking Alpha - 4/22/2021 11:22:31 AM
Amarin Receives Great Britain Marketing Authorization for VAZKEPA from the Medicines and Healthcare Products Regulatory Agenc... GlobeNewswire Inc. - 4/22/2021 10:53:02 AM
Amarin to Report First Quarter Results and Host Conference Call on April 29, 2021 GlobeNewswire Inc. - 4/20/2021 6:05:00 AM
VASCEPA® (Icosapent Ethyl) Reported to Impact Vulnerable Coronary Plaque Features in New Analyses of EVAPORATE Study Present... GlobeNewswire Inc. - 4/17/2021 9:50:00 AM
Amarin: Could the New CEO Help Vazkepa’s European Push? TipRanks - 4/13/2021 3:05:37 PM
fsulevine   Friday, 04/23/21 06:48:00 AM
Re: DAR53 post# 336582
Post # of 349005 
You have to consider it was ONLY tested for people on statins, not on its own (which I think it should be) regarding Reducie-It. Also, I would rather have a celebrity that takes it doing the endorsement... and we already signed one years ago, Rick Harrison star of the show Pawn Stars. He has been used in print ads, but it would be great if he was used in a television ad as well.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences